NEW IN VITRO SCREENING APPROACHES FOR SAFETY TESTING
3:35 Combination of Screening Assays for Assessing Drug-Induced Liver Injury in Humans
Christoph Funk, Ph.D., Vice Director, Pharmaceutical Sciences, F. Hoffmann-La Roche
Drug-induced liver injury (DILI) is one of the leading causes for acute hepatic failure and drug withdrawal. The potential DILI risk can be identified early-on by assessing multiple endpoints contributing to human DILI (metabolic activation, cytotoxicity and transporter inhibition) in conjunction with compound exposure. The approach was validated using 125 marketed or withdrawn compounds with different degree for DILI and exhibited an overall sensitivity and specificity of 80 and 86%.
4:35 Generation of Complex Disease Phenotypes in 3D Bioprinted Human Liver Tissues for the Assessment of Drug-Induced Injury
Leah Norona, Doctoral Candidate Curriculum in Toxicology, University of North Carolina at Chapel Hill
Compound-induced hepatotoxicity leading to fibrosis remains a challenge for human risk assessment. Latency to detection and limitations of conventional model systems make it difficult to characterize dynamic and complex intercellular interactions that occur during progressive injury. Here we discuss the utility of 3D bioprinted liver for studying chronic exposure using fibrosis as a case study and provide a comprehensive approach to examine key initiating events and progression of tissue injury.
I remember seeing this a while back. But he's been talking small intestine for a while.
Dr. John Geibel will be presenting on Saturday, April 4th at the International Conf. on 3D Printing in Medicine. His presentation title: "3D Bioprinting of Vessels, a new means to improve patient outcome"
2mil in bookings / 150k per contract. Although, I believe they stated some were repeat customers. So probably more like +-11 or so.
This isn't a scare tactic. This is a true story and I believe Owl was just pointing it out. Chill.